Calliditas virtual R&D Day on January 20, 2021
Key Opinion Leader (KOL) Perspectives webinar
March 10, 2021 at 10:00am Eastern Time.
Calliditas secures $75 million term loan facility
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
Learn the hidden truth about IgA nephropathy, watch videos on the source of the disease, discover the role that the gut plays in IgAN, and more.
On May 18, 2021, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2021. A conference call will be held to present and discuss the results, at 2.30 pm CEST.
Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Company number: 556659-9766
© Calliditas Therapeutics AB 2021